Elucidating the role of the complement control protein in monkeypox pathogenicity

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Hudson, Paul N ^a   Self, Joshua ^a   Weiss, Sonja ^a   Braden, Zachary ^a   Xiao, Yuhong ^b   Girgis, Natasha M ^b   Emerson, Ginny ^a   Hughes, Christine ^a   Sammons, Scott A ^a   Isaacs, Stuart N ^b   Damon, Inger K ^a   Olson, Victoria A ^a  

^a Nat Center for Emerging and Zoonotic Inf Diseases (NCEZID) and Bio Core Facility Branch   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT CONTROL PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; COMPLEMENT COMPONENT C4B BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLADISTICS; CONTROLLED STUDY; CYNOMYS LUDOVICIANUS; DISEASE COURSE; DOG; HOMOLOGOUS RECOMBINATION; MONKEYPOX; MONKEYPOX VIRUS; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; COMPLEMENT ACTIVATION; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETIC RECOMBINATION; GENETICS; IMMUNOLOGY; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PATHOGENICITY; SCIURIDAE; VIROLOGY;

CYNOMYS; MONKEYPOX VIRUS; VARIOLA VIRUS;

ANIMALS; BASE SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT C4B-BINDING PROTEIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; MALE; MOLECULAR SEQUENCE DATA; MONKEYPOX; MONKEYPOX VIRUS; OPEN READING FRAMES; RECOMBINATION, GENETIC; SCIURIDAE; VIRAL LOAD; VIRAL PROTEINS;

EID: 84859488860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035086     Document Type: Article

References (45)

1. Jezek Z, Fenner F, (1988) Human monkeypox New York Karger, Basel.
2. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, et al. (2010) Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 107: 16262-16267.
3. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M, (1987) Human monkeypox: clinical features of 282 patients. J Infect Dis 156: 293-298.
4. Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, et al. (2005) A tale of two clades: monkeypox viruses. J Gen Virol 86: 2661-2672.
5. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, et al. (2005) Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340: 46-63.
6. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, et al. (2004) The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350: 342-350.
7. Hutson CL, Lee KN, Abel J, Carroll DS, Montgomery JM, et al. (2007) Monkeypox zoonotic associations: insights from laboratory evaluation of animals associated with the multi-state US outbreak. Am J Trop Med Hyg 76: 757-768.
8. Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, et al. (2009) A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 90: 323-333.
9. Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, et al. (2006) Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol 176: 3725-3734.
10. Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, et al. (2009) Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 83: 1201-1215.
11. Bernet J, Mullick J, Singh AK, Sahu A, (2003) Viral mimicry of the complement system. J Biosci 28: 249-264.
12. Mullick J, Kadam A, Sahu A, (2003) Herpes and pox viral complement control proteins: 'the mask of self'. Trends Immunol 24: 500-507.
13. Kotwal GJ, Moss B, (1988) Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335: 176-178.
14. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B, (1990) Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250: 827-830.
15. Liszewski MK, Bertram P, Leung MK, Hauhart R, Zhang L, et al. (2008) Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment. J Immunol 181: 4199-4207.
16. Miller CG, Shchelkunov SN, Kotwal GJ, (1997) The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229: 126-133.
17. Moulton EA, Atkinson JP, Buller RM, (2008) Surviving mousepox infection requires the complement system. PLoS Pathog 4: e1000249.
18. Rosengard AM, Liu Y, Nie Z, Jimenez R, (2002) Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S A 99: 8808-8813.
19. Bernet J, Mullick J, Panse Y, Parab PB, Sahu A, (2004) Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b. J Virol 78: 9446-9457.
20. Isaacs SN, Kotwal GJ, Moss B, (1992) Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A 89: 628-632.
21. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM, (1992) Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 166: 1245-1250.
22. Mullick J, Bernet J, Panse Y, Hallihosur S, Singh AK, et al. (2005) Identification of complement regulatory domains in vaccinia virus complement control protein. J Virol 79: 12382-12393.
23. Rosengard AM, Alonso LC, Korb LC, Baldwin WM 3rd, Sanfilippo F, et al. (1999) Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Mol Immunol 36: 685-697.
24. Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD, (2005) Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol 174: 2143-2151.
25. Isaacs SN, Argyropoulos E, Sfyroera G, Mohammad S, Lambris JD, (2003) Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol 77: 8256-8262.
26. DeHaven BC, Girgis NM, Xiao Y, Hudson PN, Olson VA, et al. (2010) Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein. J Virol 84: 11245-11254.
27. Girgis NM, Dehaven BC, Xiao Y, Alexander E, Viner KM, et al. (2010) The vaccinia virus complement control protein modulates adaptive immune responses during infection. J Virol.
28. Girgis NM, Dehaven BC, Xiao Y, Alexander E, Viner KM, et al. (2010) The vaccinia virus complement control protein modulates adaptive immune responses during infection. J Virol 85: 2547-2556.
29. Toapanta FR, Ross TM, (2006) Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36: 197-210.
30. Mehlhop E, Diamond MS, (2006) Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203: 1371-1381.
31. Patel DD, Pickup DJ, Joklik WK, (1986) Isolation of cowpox virus A-type inclusions and characterization of their major protein component. Virology 149: 174-189.
32. Leite JA, da Fonseca FG, de Souza Trindade G, Abrahao JS, Arantes RM, et al. (2011) A-type inclusion bodies: a factor influencing cowpox virus lesion pathogenesis. Arch Virol 156: 617-628.
33. Boone RF, Ensinger MJ, Moss B, (1977) Synthesis of mRNA guanylyltransferase and mRNA methyltransferases in cells infected with vaccinia virus. J Virol 21: 475-483.
34. Hutson CL, Carroll DS, Self J, Weiss S, Hughes CM, et al. (2010) Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease. Virology.
35. Guarner J, Johnson BJ, Paddock CD, Shieh WJ, Goldsmith CS, et al. (2004) Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis 10: 426-431.
36. Estep RD, Messaoudi I, O'Connor MA, Li H, Sprague J, et al. (2011) Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol 85: 9527-9542.
37. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, et al. (2009) Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol 183: 3150-3159.
38. Xu RH, Cohen M, Tang Y, Lazear E, Whitbeck JC, et al. (2008) The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med 205: 981-992.
39. Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, et al. (2005) Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 73: 428-434.
40. Hruby DE, Guarino LA, Kates JR, (1979) Vaccinia virus replication. I. Requirement for the host-cell nucleus. J Virol 29: 705-715.
41. Boyle DB, Coupar BE, (1988) A dominant selectable marker for the construction of recombinant poxviruses. Gene 65: 123-128.
42. Falkner FG, Moss B, (1988) Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62: 1849-1854.
43. Chakrabarti S, Sisler JR, Moss B, (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094-1097.
44. Li Y, Olson VA, Laue T, Laker MT, Damon IK, (2006) Detection of monkeypox virus with real-time PCR assays. J Clin Virol 36: 194-203.
45. Lehmann EL, D'Abrera HJM, (1975) Nonparametrics: statistical methods based on ranks San Francisco Holden-Day. xvi, 457 p. p.